Last reviewed · How we verify

Lourdes Montero Cruces — Portfolio Competitive Intelligence Brief

Lourdes Montero Cruces pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Buckberg Cardi-Braun Buckberg Cardi-Braun marketed
Custodiol Htk Soln Custodiol Htk Soln marketed Organ preservation solution Transplantation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Dr. F. Köhler Chemie GmbH · 1 shared drug class
  2. Marc Sakwa, MD · 1 shared drug class
  3. RenJi Hospital · 1 shared drug class
  4. Rigshospitalet, Denmark · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lourdes Montero Cruces:

Cite this brief

Drug Landscape (2026). Lourdes Montero Cruces — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lourdes-montero-cruces. Accessed 2026-05-16.

Related